Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States | Vaccine Adverse Event Reporting System |
---|---|
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-Cov-2 variants | Centers for Disease Control and Prevention |
COVID-19 vaccine reactions: The difference between common and allergic reactions.
23Vaccine adverse event reporting system VAERS | COVID-19 vaccines and allergic reactions |
---|---|
Centers for Disease Control and Prevention | Use of Pfizer-BioNTech COVID-19 vaccine: Clinical considerations |
COVID-19 vaccines vs variants — Determining how much immunity is enough.
12